TTD, OCGN, STZ, VRTX, LCID Trending With Analysts

Analysts are intrested in these 5 stocks: ( (TTD) ), ( (OCGN) ), ( (STZ) ), ( (VRTX) ) and ( (LCID) ). Here is a breakdown of their recent ratings and the rationale behind them.

Trade Desk (TTD) has slipped out of favor with Stifel’s Mark Kelley, who downgraded the stock to Hold and set a $26 target. The trigger was a damaging audit for major client Publicis, which accused TTD of misapplying fees and auto‑enrolling clients in paid features, raising doubts about near‑term growth and sentiment despite TTD still being seen as the “gold standard” in digital ad buying.

Kelley notes Publicis accounts for more than 10% of TTD’s billings and was central to a 2026 revenue acceleration story driven by political ad spending and a stable client base. While he expects some resolution and points to TTD’s direct brand relationships and SOC 1‑backed billing controls, he sees an uncertain catalyst path and subdued sentiment as negative headlines pile up, keeping investors on the sidelines for now.

Ocugen (OCGN) is getting a second look from Canaccord Genuity’s Whitney Ijem, who initiated coverage with a Buy and a $12 price target. After a dilutive and winding past, the company now has three clinical‑stage eye gene therapies that have produced promising early data, positioning OCGN as a speculative but potentially rewarding play in retinal diseases.

Ijem is particularly bullish on OCU410ST in Stargardt disease, where Phase 1 data showed slower lesion growth and better visual acuity ahead of key Phase 2/3 data in 3Q26, and sees upside from related programs in geographic atrophy and retinitis pigmentosa. With roughly $41 million pro forma cash carrying OCGN into late 2026 and valuation built from peak sales across three assets, the analyst views upcoming readouts as multiple catalysts that could re‑rate the stock.

Constellation Brands (STZ) has won back favor at Citi, where analyst Filippo Falorni upgraded the stock to Buy and lifted the target price to $175. He sees a turning point in the beer business, with scanner data showing improving sales and volumes, easier 2026 comparisons, and extra tailwinds from a Hispanic consumer recovery and the FIFA World Cup.

Falorni argues that consensus underestimates both volume recovery and margin strength, noting beer operating margin guidance looks conservative and that pricing and cost savings could offset headwinds from aluminum, FX, and depreciation. With STZ trading around 12 times forward earnings versus a five‑year average near 18 times and a new CEO potentially resetting expectations, he believes investors are being paid to bet on a summer‑driven beer rebound.

Vertex Pharmaceuticals (VRTX) is back in the spotlight after analyst Naz Rahman upgraded the stock to Buy and set a $575 target, citing blockbuster potential from its kidney drug candidate povetacicept. Interim Phase 3 data in IgA nephropathy showed powerful reductions in proteinuria and disease‑related biomarkers, and Vertex plans to finish a rolling BLA by the end of March aiming for approval as soon as late 2026.

Rahman believes povetacicept, together with cell and gene therapies Journavx and Casgevy, can generate more than 30% of Vertex’s revenue by 2030 and finally diversify the company beyond cystic fibrosis. While VRTX already trades at a premium multiple near 24 times 2026 earnings, the analyst expects further re‑rating as investors price in a durable CF core, $12.3 billion in cash with no debt, and a growing portfolio of high‑margin, high‑growth products.

Lucid Group (LCID) is being framed as a high‑risk, high‑reward turnaround by Citi’s Michael Ward, who initiated coverage with a Buy and a $17 price target. He argues the electric‑vehicle maker is at a positive inflection point, with the Gravity SUV launched, the mass‑market Cosmos set for 4Q26 production, and an Uber robotaxi partnership expected to go commercial by year‑end.

Ward points to accelerating European expansion in 2026, monthly autonomous‑driving subscriptions planned for 2027, and strong backing from Saudi Arabia’s PIF as supports through heavy investment years. Lucid burned $3.8 billion in cash last year and is likely to need more capital despite $4.6 billion in liquidity, but the analyst values the stock at a modest multiple to forward revenue versus other non‑Tesla EV peers, arguing that product momentum could outweigh funding fears for investors willing to stomach volatility.